Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Translational Research
- Vol. 229, 135-141
Abstract
No abstract availableKeywords
Funding Information
- Universitat de València
This publication has 54 references indexed in Scilit:
- Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label TrialThe Cerebellum, 2013
- Flavin Adenine Dinucleotide Rescues the Phenotype of Frataxin DeficiencyPLOS ONE, 2010
- Molecular control of the cytosolic aconitase/IRP1 switch by extramitochondrial frataxinHuman Molecular Genetics, 2010
- Alpha-lipoic acid and frataxin: A new indication for an old antioxidant?Experimental Neurology, 2009
- Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathyExperimental Neurology, 2008
- The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathiesAdvanced Drug Delivery Reviews, 2008
- Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disordersMuscle & Nerve, 2007
- L-carnitine and creatine in Friedreich’s ataxia. A randomized, placebo-controlled crossover trialJournal of Neural Transmission, 2004
- Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxiaNature Genetics, 1997
- Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxinNature Genetics, 1997